Self-guided fear-of-recurrence program falls short for ovarian cancer survivors
Fear of cancer recurrence can dominate survivorship long after treatment ends, and ovarian cancer survivors are no exception. In this pilot randomized waitlist-controlled trial, the self-guided digital intervention iConquerFear struggled to clear the first hurdle: getting women to use it consistently enough to judge its therapeutic value with confidence.
Stage I-III ovarian cancer survivors were recruited through Ovarian Cancer Australia between October and December 2022 and randomized to immediate access or an 8-week waitlist. The trial was designed to test feasibility, acceptability, and safety before any broader claim could be made about symptom relief. Across the enrolled group, the burden of distress was obvious from the start. At baseline, 55% of the 55 randomized participants met the threshold for severe fear of cancer recurrence, a reminder that survivorship after ovarian cancer often involves persistent threat monitoring rather than a clean return to normal life.
Engagement was the central barrier
Of 62 eligible survivors, 55 were randomized, with 29 assigned to the intervention arm and 26 to the waitlist control. Only 28 of those randomized actually accessed iConquerFear. Even among users, completion lagged behind what a self-guided psychological program would need to succeed: 16 of 28 users completed at least three of the five modules. In practical terms, this means the intervention was not just asking survivors to log on once; it required repeated emotional engagement with a topic many people already avoid in daily life.
The pattern makes clinical sense. Fear of recurrence is not a narrow informational gap. It is a deeply conditioned response shaped by prior diagnosis, surveillance scans, ambiguous bodily sensations, and the chronic uncertainty of ovarian cancer follow-up. A digital module may offer structure and convenience, but it cannot easily match the reassurance, tailoring, and emotional containment of a live therapeutic exchange when the subject is fear itself.
Acceptability was moderate, not compelling
Mean post-intervention acceptability on the IEUQ was 3 out of 4, with a standard deviation of 0.8. On paper, that sounds respectable. In a sensitive psycho-oncology intervention, though, average acceptability does not automatically translate into meaningful adoption or safe implementation. The study also recorded qualitative feedback from 13 participants, and those interviews identified six key themes, including participant factors that influenced engagement. The design of the program clearly interacted with individual readiness, personal coping style, and the emotional load carried by each survivor.
One sentence captures the operational problem. Self-guided support was not enough for a substantial subset of participants.
The intervention’s format likely matters here. Fear of recurrence often involves cyclical worry, hypervigilance to symptoms, and a tendency to scan for danger in ordinary experiences. A digital platform can present cognitive and behavioral tools, but it may also leave participants alone with the very thoughts they were hoping to quiet. For some survivors, that isolation may be part of the problem rather than the solution.
Distress-related withdrawal raises safety concerns
Safety was not a side issue in this study. Three users, representing 11% of the intervention users, withdrew because the program itself caused distress. For a mental health or psycho-oncology intervention, that is a meaningful signal. The content was presumably intended to reduce fear, yet for a subset of survivors it appears to have intensified discomfort enough to stop participation.
This does not invalidate digital care as a concept, but it does place a hard boundary around what self-guided care can safely accomplish in a high-distress population. Ovarian cancer survivors live with a disease that often carries a heavy recurrence burden and substantial uncertainty around symptoms and surveillance. In that setting, an intervention that asks patients to confront threat-related cognitions without real-time support may exceed what some can tolerate. A stepped model with clinician backup, peer support, or embedded escalation pathways may be more appropriate than a standalone product.
No clear signal of symptom improvement emerged
The exploratory comparison between intervention and control groups did not show significant differences in changes in fear of cancer recurrence or progression. That null finding should be read in context: this was a pilot study, not a definitive efficacy trial. Still, when combined with low uptake, partial completion, and distress-related discontinuation, the absence of a clear signal becomes more than a statistical footnote. It suggests the intervention’s current format may not deliver enough therapeutic exposure to move the outcome that matters most.
The trial’s structure also limited what could be learned about dose-response. If only about half of randomized participants used the program at all, and fewer than that completed most modules, it becomes difficult to know whether the content failed, the delivery model failed, or both. In psycho-oncology, those two questions are often inseparable. The treatment must be potent enough to matter and tolerable enough to be used.
What ovarian cancer survivorship care may need instead
The findings point toward a different model for fear-of-recurrence care in ovarian cancer. A fully self-guided digital program may be too blunt an instrument for a symptom domain defined by anxiety, uncertainty, and emotional vulnerability. Complementary in-person support, facilitated check-ins, or a blended model could help match intensity to need. Some survivors may benefit from digital access as an entry point, but others will likely require human contact to stay engaged long enough for the therapeutic work to take hold.
The study was registered with ANZCTR on 21 April 2022 and offers a useful early warning for the field. Digital mental health tools are often appealing because they scale easily and can be delivered between clinic visits. Yet ovarian cancer survivorship care cannot be judged by scalability alone. If an intervention drives distress, loses engagement quickly, and fails to separate from control on the outcome it was built to improve, its real-world value is limited in its current form.
For now, iConquerFear appears better suited as a prototype than a ready-to-deploy solution for ovarian cancer survivors coping with fear of recurrence. The next version will need more than digital convenience; it will need a safer pathway for emotionally fragile patients, stronger retention, and a support structure that recognizes how intense this fear can be when the disease has already changed a life once.